Biophysical and immunological characterization of the ESX-4 system ESAT-6 family proteins Rv3444c and Rv3445c from Mycobacterium tuberculosis H37Rv

Pandey, Himanshu; Fatma, Farheen; Yabaji, Shivraj M.; Kumari, Monika; Tripathi, Sarita; Srivastava, Kirti; Tripathi, Dinesh Kumar; Kant, Surya; Arora, Ashish

doi:10.1016/j.tube.2018.02.002

Cited by 10 publications

(3 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The search for cross-protective or universal vaccines is an active topic of investigation. Examples include Plasmodium vivax and P. falciparum vaccines (40), S. pneumoniae (PspA) (41), schistosomes (42), the long a-helix of influenza hemagglutinin (43), and protective Ags of Mycobacterium tuberculosis (44). Applying our structure-based approach to this common protein motif may improve the predictions of other investigators searching for broadly protective vaccine Ags.…”

Section: Discussionmentioning

confidence: 99%

Design of Broadly Cross-Reactive M Protein–Based Group A Streptococcal Vaccines

Aranha

Penfound

Salehi

et al. 2021

The Journal of Immunology

View full text Add to dashboard Cite

Group A streptococcal infections are a significant cause of global morbidity and mortality. A leading vaccine candidate is the surface M protein, a major virulence determinant and protective Ag. One obstacle to the development of M protein–based vaccines is the >200 different M types defined by the N-terminal sequences that contain protective epitopes. Despite sequence variability, M proteins share coiled-coil structural motifs that bind host proteins required for virulence. In this study, we exploit this potential Achilles heel of conserved structure to predict cross-reactive M peptides that could serve as broadly protective vaccine Ags. Combining sequences with structural predictions, six heterologous M peptides in a sequence-related cluster were predicted to elicit cross-reactive Abs with the remaining five nonvaccine M types in the cluster. The six-valent vaccine elicited Abs in rabbits that reacted with all 11 M peptides in the cluster and functional opsonic Abs against vaccine and nonvaccine M types in the cluster. We next immunized mice with four sequence-unrelated M peptides predicted to contain different coiled-coil propensities and tested the antisera for cross-reactivity against 41 heterologous M peptides. Based on these results, we developed an improved algorithm to select cross-reactive peptide pairs using additional parameters of coiled-coil length and propensity. The revised algorithm accurately predicted cross-reactive Ab binding, improving the Matthews correlation coefficient from 0.42 to 0.74. These results form the basis for selecting the minimum number of N-terminal M peptides to include in potentially broadly efficacious multivalent vaccines that could impact the overall global burden of group A streptococcal diseases.

show abstract

Section: Discussionmentioning

confidence: 99%

Design of Broadly Cross-Reactive M Protein–Based Group A Streptococcal Vaccines

Aranha

Penfound

Salehi

et al. 2021

The Journal of Immunology

View full text Add to dashboard Cite

show abstract

“…Dascher et al (2003) developed a vaccine which included lipids from Mycobacterium tuberculosis that were incorporated into liposomes with an adjuvant; the studies using a guinea pig aerosol tuberculosis challenge model demonstrated that lipid antigens play an important role in the immune response to tuberculosis infection, potentially through the production of CD1-restricted T cells. In addition, the Mycobacterium tuberculosis 6-kilodalton early secreted antigenic target protein (ESAT-6) is considered to be an important mediator in mycobacterial virulence, has strong antigenicity, and can induce a protective Th1 immune response against Mycobacterium tuberculosis (Pandey et al, 2018). Khader et al (2007) vaccinated mice with an ESAT-6 peptide (amino acids 1–20 of ESAT-6) in an adjuvant composed of MPLA, trehalose dicorynomycolate, and dimethyl dioctadecylammonium bromide.…”

Section: Toll-like Receptor Agonists As Built-in Adjuvantsmentioning

confidence: 99%

Application of built-in adjuvants for epitope-based vaccines

Yao

Zhao

Shao

et al. 2019

PeerJ

View full text Add to dashboard Cite

Several studies have shown that epitope vaccines exhibit substantial advantages over conventional vaccines. However, epitope vaccines are associated with limited immunity, which can be overcome by conjugating antigenic epitopes with built-in adjuvants (e.g., some carrier proteins or new biomaterials) with special properties, including immunologic specificity, good biosecurity and biocompatibility, and the ability to vastly improve the immune response of epitope vaccines. When designing epitope vaccines, the following types of built-in adjuvants are typically considered: (1) pattern recognition receptor ligands (i.e., toll-like receptors); (2) virus-like particle carrier platforms; (3) bacterial toxin proteins; and (4) novel potential delivery systems (e.g., self-assembled peptide nanoparticles, lipid core peptides, and polymeric or inorganic nanoparticles). This review primarily discusses the current and prospective applications of these built-in adjuvants (i.e., biological carriers) to provide some references for the future design of epitope-based vaccines.

show abstract

“…Dascher et al developed a vaccine which included lipids from M. tuberculosis that were incorporated into liposomes with an adjuvant; the studies using a guinea pig aerosol tuberculosis challenge model demonstrated that lipid antigens play an important role in the immune response to tuberculosis infection, potentially through the production of CD1-restricted T cells (Dascher et al, 2003). In addition, the M. tuberculosis 6-kilodalton early secreted antigenic target protein (ESAT-6) is considered to be an important mediator in mycobacterial virulence, has strong antigenicity, and can induce a protective Th1 immune response against M. tuberculosis (Pandey et al, 2018). Khader et al vaccinated mice with an ESAT-6 peptide (amino acids 1 -20 of ESAT-6) in an adjuvant composed of monophosphoryl lipid A (MPL), trehalose dicorynomycolate (TDM), and dimethyl dioctadecylammonium bromide (DDA).…”

Section: Heparin-binding Hemagglutinin (Hbha)mentioning

confidence: 99%

Peer Review #3 of "Application of built-in adjuvants for epitope-based vaccines (v0.1)"

Banday¹

2019

View full text Add to dashboard Cite

Several studies have shown that epitope vaccines exhibit substantial advantages over conventional vaccines. However, epitope vaccines are associated with limited immunity, which can be overcome by conjugating antigenic epitopes with built-in adjuvants (e.g., some carrier proteins or new biomaterials) with special properties, including immunologic specificity, good biosecurity and biocompatibility, and the ability to vastly improve the immune response of epitope vaccines. When designing epitope vaccines, the following types of built-in adjuvants are typically considered: 1) pattern recognition receptor (PRR) ligands (i.e., toll-like receptors [TLRs]); 2) virus-like particle (VLP) carrier platforms; 3) bacterial toxin proteins; and 4) novel potential delivery systems (e.g., self-assembled peptide nanoparticles [SAPNs], lipid core peptides [LCPs], and polymeric or inorganic nanoparticles). This review primarily discusses the current and prospective applications of these built-in adjuvants (i.e., biological carriers) to provide some references for the future design of epitope-based vaccines.

show abstract

Biophysical and immunological characterization of the ESX-4 system ESAT-6 family proteins Rv3444c and Rv3445c from Mycobacterium tuberculosis H37Rv

Cited by 10 publications

References 48 publications

Design of Broadly Cross-Reactive M Protein–Based Group A Streptococcal Vaccines

Design of Broadly Cross-Reactive M Protein–Based Group A Streptococcal Vaccines

Application of built-in adjuvants for epitope-based vaccines

Peer Review #3 of "Application of built-in adjuvants for epitope-based vaccines (v0.1)"

Contact Info

Product

Resources

About